Claret Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Claret Asset Management's REGN Position: Q2 2026 in Review
Claret Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q2 2026, selling an estimated $55.8K and leaving 357 shares worth $223K. The position accounts for 0.02% of the portfolio, ranked #443.
Claret Asset Management first reported a position in REGN in Q2 2024 and has held it in 7 quarters since. The position peaked at $339K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Claret Asset Management held 357 shares of Regeneron Pharmaceuticals worth $223K as of Q2 2026.
- Claret Asset Management sold 82 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $55.8K.
- Regeneron Pharmaceuticals made up 0.02% of Claret Asset Management's portfolio in Q2 2026, its #443 holding.
- Claret Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
- Claret Asset Management's Regeneron Pharmaceuticals position peaked at $339K in Q1 2026.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.